CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
CORCEPT THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
Share price
+$33.41 (+42.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CORCEPT THERAPEUTICS INC grew revenue 16.0% to $830.81M over the twelve months to Jun 30, 2026. Operating income fell 93.7% to $6.41M, moving the operating margin from 14.2% to 0.8%. Free cash flow was $106.92M, down 40.8% from a year earlier.
Revenue
$830.81M
+16.0% vs. a year earlier
Operating income
$6.41M
-93.7% vs. a year earlier
Free cash flow
$106.92M
-40.8% vs. a year earlier
EPS, diluted
$0.42
-62.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $13.27B
- P/E ratio
- 266.9
- Price to sales
- 15.97
- Price to book
- 18.80
- Dividend yield
- –
- Free cash flow yield
- 0.81%
Fundamentals
- Revenue
- $830.81M
- Net income
- $55.18M
- EPS, diluted
- $0.42
- Free cash flow
- $106.92M
- Book value per share
- $5.96
- Diluted shares
- 118M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$830.81M+16.0% YoY
Gross profit
$816.73M+15.9% YoY
Operating income
$6.41M-93.7% YoY
Net income
$55.18M-58.7% YoY
EPS, diluted
$0.42-62.5% YoY
Free cash flow
$106.92M-40.8% YoY
Reported periodTrailing twelve months